Vigil Neuroscience, Inc.

    Vigil Neuroscience, Inc.

    NNASDAQ:VIGL
    8.05
    USD
    0.00
    (0.00%)
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    - -
    -1.53
    -2.16
    -2.13
    -2.07
    -2.1
    Free Cash Flow per Basic Share
    - -
    -1.4
    -2.09
    -1.84
    -1.26
    -1.33
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    - -
    -2.54
    -4.42
    -5.75
    -7.55
    -8.1
    Tangible Book Value per Share
    - -
    -2.46
    5.97
    3
    1.76
    0.94
    Basic Weighted Avg Shares
    - -
    28
    32
    39
    41
    44
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    Net Income, GAAP
    - -
    -43
    -68
    -83
    -84
    -92
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Working Capital
    23
    88
    186
    110
    66
    36
    LT Debt
    - -
    - -
    - -
    13
    12
    11
    Total Equity
    -28
    -69
    189
    116
    72
    41
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    ST Debt
    1
    1
    1
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    12
    12
    11
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    41
    47
    47
    Market Capitalization
    69
    75
    350

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    Total Current Assets
    101
    90
    70
    Cash, Cash Equivalents & STI
    98
    87
    67
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    34
    30
    34
    Payables & Accruals
    13
    9
    13
    ST Debt
    1
    1
    1
    Deferred Revenue
    20
    20
    20

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -38.38%
    Free Cash Flow
    - -
    - -
    -27.89%
    Net Income, GAAP
    - -
    - -
    1.96%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.51
    -0.52
    -0.53
    - -
    -2.13
    2024
    -0.5
    -0.52
    -0.47
    -0.57
    -2.07
    2025
    -0.49
    -0.56
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

    • zacks.com

      Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

    • prnewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

    • zacks.com

      Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

    • prnewswire.com

      VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

    • globenewswire.com

      Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

    • zacks.com

      Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

    • globenewswire.com

      $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

    • zacks.com

      Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade

    • businesswire.com

      VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

    • businesswire.com

      Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders

    • businesswire.com

      VIGL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Vigil Neuroscience, Inc. is Fair to Shareholders

    • wsj.com

      Sanofi to Buy Vigil Neuroscience for About $470 Million

    • globenewswire.com

      Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    • reuters.com

      Sanofi to acquire Vigil Neuroscience in $470 million deal

    • globenewswire.com

      Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

    • globenewswire.com

      Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

    • zacks.com

      Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know

    • globenewswire.com

      Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

    • globenewswire.com

      Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum